V89L Polymorphism of the 5α-Reductase Type II Gene (SRD5A2), Endogenous Sex Hormones, and Prostate Cancer Risk.

The article focuses on the results of a study which examined the combined effect of circulating sex hormones and SRD5A2 V89L polymorphism on prostate cancer risk. It notes that prostate cancer is the most common cancer and is the second most common cause of cancer mortality in men in the U.S. It associates above-median serum levels of dehydroepiandrosterone sulfate (DHEAS) and 3α-diol with the risk of aggressive prostate cancer.